At Centauri we seek to tackle life-threatening infectious diseases in the most vulnerable patients.

Learn more
Alphamers

Our science

Centauri Therapeutics is an immunotherapy company focused on infectious diseases. Centauri’s approach to treating infectious diseases rests upon proprietary Alphamer® technology. All projects harness a powerful and clinically validated immune mechanism which redirects naturally existing antibodies to treat life-threatening diseases.

7.0m

immunocompromised people in the United States 1

60%

of haematological cancer deaths are infection related 2

$4.6bn

health care costs in the US to treat six antibiotic resistance threats 3

67,000

deaths annually in Europe and US due to drug-resistant bacterial infections 4 5

Bacteria

Latest News and Articles

Centauri Therapeutics attended ID Week 2022

October 27, 2022

Jennifer Schneider, CEO and Helen Bright, VP of Research &…

Read More

Centauri Therapeutics Dr Mike Westby attended ESCMID/ASM Conference 2022

October 27, 2022

Dublin, 4th to 7th October 2022 – Dr Mike Westby, Centauri’s…

Read More

Centauri welcomes Alison Gallop

October 17, 2022

Centauri is pleased to welcome Alison Gallop to the team…

Read More

Citations

1. https://www.ama-assn.org/delivering-care/public-health/what-tell-immunocompromised-patients-about-covid-19-vaccines

2. Zembower, T.R. (2014). Epidemiology of Infections in Cancer Patients. In: Stosor, V., Zembower, T. (eds) Infectious Complications in Cancer Patients. Cancer Treatment and Research, vol 161. Springer, Cham https://doi.org/10.1007/978-3-319-04220-6_2

3. https://www.cdc.gov/drugresistance/solutions-initiative/stories/partnership-estimates-healthcare-cost.html

4. https://www.euro.who.int/en/health-topics/disease-prevention/pages/news/news/2022/01/whoecdc-report-antimicrobial-resistance-remains-threat-to-health-in-european-region

5. https://www.cdc.gov/media/releases/2019/p1113-antibiotic-resistant.html